Langley RG, et al. - In patients with psoriasis who had inadequate responses to ustekinumab, authors assessed the effectiveness and safety of brodalumab through week 52. They performed a subgroup analysis of phase 3 AMAGINE-2/-3 double-blind randomized controlled trials. Compared with continuing ustekinumab, an improvement in the skin clearance outcomes was seen with brodalumab among patients who experienced inadequate responses to ustekinumab. Among these patients, psoriasis area and severity index in those rescued with brodalumab was 75%, 90%, and 100% improvement response rates were 72.6%, 58.1%, and 36.3%, respectively, at week 52 compared with 61.7%, 25.5%, and 5.4%, respectively, in patients who continued ustekinumab.